Vitamin D

Healthy adults under the age of 75 are unlikely to benefit from taking more than the daily intake of vitamin D recommended by the Institutes of Medicine (IOM) and do not require testing for vitamin D levels. For children, pregnant people, adults older than 75 years and adults with high-risk prediabetes, the guideline recommends vitamin D higher than the IOM recommended daily allowance. Healthy adults under the age of 75 are unlikely to benefit from taking more than the daily intake of vitamin D recommended by the Institutes of Medicine (IOM) and do not require testing for vitamin D levels, according to a new Clinical Practice Guideline issued today by the Endocrine Society. For children, pregnant people, adults older than 75 years and adults with high-risk prediabetes, the guideline recommends vitamin D higher than the IOM recommended daily allowance. Vitamin D use and blood vitamin D levels have been associated with many common diseases. However, whether vitamin D supplementation lowers the risk of these diseases and what vitamin D blood levels are needed for better health have been debated for years. In this new guideline, the panel of experts established guidelines for vitamin D use and testing for vitamin D levels in healthy persons without established indications for vitamin D treatment or testing. The guideline relied on clinical trials to develop the recommendations. The guideline, titled "Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline," was published online and will appear in the August 2024 print issue of The Journal of Clinical Endocrinology & Metabolism (JCEM), a publication of the Endocrine Society. "The goal of this guideline was to address the vitamin D requirements for disease prevention in a generally healthy population with no underlying conditions that would put them at risk of impaired vitamin D absorption or action," said Marie Demay, M.D., of Harvard Medical School and Massachusetts General Hospital in Boston, Mass. Demay is the chair of the panel that developed the guideline. "Healthy populations who may benefit from higher dose vitamin D supplements are those 75 and older, pregnant people, adults with prediabetes, and children and adolescents 18 and younger, but we do not recommend routine testing for vitamin D levels in any of these groups." Key recommendations from the guideline include: Even though the evidence on the role of vitamin D in health and disease has increased over the last decade, the panel noted many limitations in the available evidence. For example, many of the large clinical trials were not designed for several of the outcomes that they reported, and the studied populations had vitamin D blood levels that most would consider adequate to begin with. Based on insufficient evidence, the panel could not determine specific blood-level thresholds for 25-hydroxyvitamin D for adequacy or for target levels for disease prevention. Other members of the Endocrine Society writing committee that developed this guideline include: Anastassios Pittas (co-chair) of Tufts Medical Center in Boston, Mass.; Daniel Bikle of the University of California San Francisco in San Francisco, Calif.; Dima Diab of the University of Cincinnati in Cincinnati, Ohio; Mairead Kiely of University College Cork in Cork, Ireland; Marise Lazaretti-Castro of Universidade Federal de Sao Paulo in Sao Paulo, Brazil; Paul Lips of Amsterdam University Medical Center in Amsterdam, Netherlands; Deborah Mitchell of Massachusetts General Hospital and Harvard Medical School in Boston, Mass.; M. Hassan Murad of the Mayo Clinic in Rochester, Minn.; Shelley Powers of American Bone Health in Raleigh, N.C.; Sudhaker Rao of Henry Ford Health in Detroit, Mich. and Michigan State University in Lansing, Mich.; Robert Scragg of The University of Auckland in Auckland, New Zealand; John Tayek of Harbor-University of California Los Angeles Medical Center in Torrance, Calif.; Amy Valent of Oregon Health & Science University in Portland, Ore.; Judith Walsh of the University of California San Francisco in San Francisco, Calif.; and Christopher McCartney of West Virginia University in Morgantown, W.Va.

TAMPA, Fla., May 30, 2024 /PRNewswire/ -- A new review in the journal Practical Neurology highlights the efficacy of the supplement Petadolex in preventing migraines. The comprehensive review of "Nutraceuticals for Migraine Management" conducted by headache specialists Drs L. Denysenko and D. Kuruvilla details the effectiveness of four widely available supplements commonly used for migraine prevention. Only Petadolex has data to support reducing migraine frequency with "a predictable dose-response relationship." Continue Reading Only Petadolex has data to support reducing migraine frequency with "a predictable dose-response relationship." Post this Petadolex Butterbur Supplement Proven Effective for Migraine Management Petadolex, a patented preparation of the European butterbur plant, was compared to Coenzyme Q10 (CoQ10), Vitamin D, and Curcumin. Petadolex stands out with numerous clinical trials demonstrating its safety and efficacy as well as laboratory studies showing how and why it works. While Petadolex is derived from butterbur, unlike other available or generic butterbur supplements, it is a proprietary liquid extract of the plant which ensures that potentially toxic native butterbur chemicals are eliminated. The resulting supplement, Petadolex, has reliable, safe and effective pharmacology and contains a minimum 15% petasins and isopetasins, the essential active ingredients proven effective in patient studies. Petadolex, the only liquid form of butterbur used in clinical trials, has been shown to work by multiple mechanisms including inhibiting the release of calcitonin gene-related peptide (CGRP). CGRP, the brain chemical which plays a key role in causing migraine symptoms, is blocked or inhibited by the newest category of migraine prevention prescription drugs. Modifying CGRP is also a natural mechanism of Petadolex as well as blocking migraines by acting on select calcium channel pathways to desensitize sensory neurons. Dr. Lex Denysenko, the lead author of the review, notes: "Our review highlights the potential of butterbur liquid extract, particularly Petadolex, in migraine management. The evidence suggests butterbur may offer a valuable therapy for reducing migraine frequency and improving patient outcomes." For clinicians and individuals seeking natural alternatives to prescription drugs, Petadolex holds promise as a natural remedy for migraine prevention. To learn more about Petadolex and the benefits of its butterbur extract, visit . References About Petadolex Petadolex® butterbur supplement, manufactured by Linpharma, provides premium quality and efficacy for your health needs. Produced in Germany, where supplements are held to the same rigorous standards as medications, our products meet stringent safety and ingredient-purity benchmarks surpassing U.S. standards and domestically manufactured supplements. Backed by Weber & Weber, a renowned German OTC company with over 60 years of expertise in pharmaceuticals, herbal extracts, homeopathic products, and dietary supplements, Linpharma proudly represents these exceptional products in the USA and Canada. Learn more at SOURCE Linpharma